*In a 68- and 72-week clinical trial of Wegovy (2.4 mg) and Zepbound (15 mg) for patients with BMI ≥30 or BMI ≥27 with a weight-related condition and no diabetes, average weight loss was 15% and 20%, respectively, versus 2.4% and 3.1% with diet and exercise alone.
